Hughes W T, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur R J, Pratt C, George S L
N Engl J Med. 1977 Dec 29;297(26):1419-26. doi: 10.1056/NEJM197712292972602.
In a randomized, double-blind, placebocontrolled study to evaluate the efficacy of trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia, we studied 160 patients with cancer who were at high risk for this pneumonia over a two-year period. Seventeen of the 80 patients receiving a placebo acquired P. carinii pneumonitis, whereas none of the 80 given 150 mg of trimethoprim and 750 mg of sulfamethoxazole per square meter per day had the infection P less than 0.01). Bacterial sepsis, pneumonia other than that caused by P. carinii, acute otitis media, upper-respiratory-tract infections, sinusitis and cellulitis occurred less frequently in recipients of the drug than in the placebo group (P less than 0.01 in each case). Oral candidiasis was the only adverse effect ecountered from trimethoprim-sulfamethoxazole administration. The study shows the combination to be highly effective in the prevention of P. carinii pneumonitis.
在一项评估甲氧苄啶-磺胺甲恶唑预防卡氏肺孢子虫肺炎疗效的随机、双盲、安慰剂对照研究中，我们在两年时间里对160例患这种肺炎高危的癌症患者进行了研究。80例接受安慰剂的患者中有17例患上卡氏肺孢子虫肺炎，而80例每天每平方米给予150毫克甲氧苄啶和750毫克磺胺甲恶唑的患者均未发生感染（P<0.01）。药物接受者中细菌败血症、非卡氏肺孢子虫引起的肺炎、急性中耳炎、上呼吸道感染、鼻窦炎和蜂窝织炎的发生率低于安慰剂组（每种情况P<0.01）。口服念珠菌病是甲氧苄啶-磺胺甲恶唑给药唯一遇到的不良反应。该研究表明该联合用药在预防卡氏肺孢子虫肺炎方面非常有效。
